GlassScriptPhysician profile
Melissa Layser
NPI 1750989869
$886.42
in general payments reported to CMS, 2019-2025
12 companies · $38.75 in 2025
The $38.75 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.39 · 2022: $121 · 2023: $230 · 2024: $457 · 2025: $38.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.55 | 2023-2024 | Relistor |
| Kerecis Limited | $141.99 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Boston Scientific Corporation | $138.60 | 2024 | Wavewriter Alpha Prime 16 |
| Integra Lifesciences Corporation | $100.04 | 2022 | |
| Smith+Nephew, INC. | $77.11 | 2021-2023 | Collagenase Santyl, Regranex |
| Forte Bio-Pharma LLC | $50.66 | 2024 | Prolate, Nalocet |
| Spr Therapeutics, INC | $38.75 | 2025 | Sprint Pns System |
| Acera Surgical, INC. | $22.68 | 2023 | Restrata Wound Matrix |
| Bioventus LLC | $22.43 | 2024 | Durolane |
| Merz North America, INC. | $18.39 | 2024 | |
| Kci USA, INC. | $15.54 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.68 | 2024 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Layser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.